Kadmon’s belumodsil curbed graft-versus-host disease in nearly three-quarters of patients in a pivotal study, teeing up an FDA filing in the fourth quarter.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,